Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer  with Epidermal Growth Factor Receptor Gene Mutation].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Mar 2022

Huang Junxia, Wang Hong

Abstract excerpt

Lung cancer is the sixth leading cause of death worldwide and one of the leading cause of death from malignant tumors. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) gene mutation is a common mutation in NSCLC. For advanced NSCLC patients with EGFR mutations, EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as Gefitinib, Afatinib, Oxitinib and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Genes, erbB-1

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 35340161
DOI: 10.3779/j.issn.1009-3419.2022.101.05
PMCID: PMC8976207

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].PMID 35340161Read ↗

[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].Semantic proximity Read ↗

[Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].Semantic proximity Read ↗

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.Semantic proximity Read ↗

[Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].Semantic proximity Read ↗

[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].Semantic proximity Read ↗

The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancerSemantic proximity Read ↗

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.Semantic proximity Read ↗

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].Semantic proximity Read ↗

[Advances in research on primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients].Semantic proximity Read ↗

[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.Semantic proximity Read ↗

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.